New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ABBV;RHHBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 23, 2015
10:02 EDTABBVAbbVie says communication with Johnson & Johnson has been 'very positive'
Subscribe for More Information
09:38 EDTABBVAbbVie says cutting Humira spending 'not a prudent strategy'
Subscribe for More Information
09:29 EDTABBVAbbVie sees Q2 EPS $1.04-$1.06, consensus $1.05
Subscribe for More Information
09:26 EDTABBVAbbVie says not completly immune to forex, but hedges protect bottom line impact
Subscribe for More Information
09:16 EDTABBVAbbVie says intends to enforce IP if Humira challenged by biosimilar applicant
Subscribe for More Information
09:07 EDTABBVAbbVie says remains on track to complete Pharmacyclics acquisition in Q2
09:04 EDTABBVAbbVie says continues to see strong underlying demand for Humira
Comment from earnings conference call.
08:19 EDTABBVEnanta announces FDA grants priority review for AbbVie treatment regimen
Subscribe for More Information
07:52 EDTABBVAbbVie expects Pharmacyclics transaction to close in Q2
Subscribe for More Information
07:51 EDTABBVAbbVie raises FY15 adjusted EPS to $4.10-$4.30 from $4.05-$4.25, consensus $4.19
Subscribe for More Information
07:51 EDTABBVAbbVie reports Q1 HUMIRA sales up 26% to $3.11B
Subscribe for More Information
07:49 EDTABBVAbbVie reports Q1 adjusted EPS 94c, consensus 85c
Reports Q1 revenue $5.04B, consensus $4.98B
April 22, 2015
15:50 EDTABBVNotable companies reporting before tomorrow's open
Subscribe for More Information
14:08 EDTABBVEarnings Watch: AbbVie's Humira sales will be focus for Q1
Subscribe for More Information
08:55 EDTABBVDeutsche Bank biotech analyst holds an analyst/industry conference call
Subscribe for More Information
07:07 EDTABBVEuropean Association for the Study of the Liver to hold annual meeting
50th Annual Meeting of EASL will be held in Vienna, Austria on April 22-26.
05:27 EDTRHHBYRoche sees FY15 core EPS to grow ahead of sales at constant exchange rates
Expects FY15 sales to grow low- to mid-single digit, at constant exchange rates. Roche expects to further increase its dividend in Swiss francs.
05:27 EDTRHHBYRoche reports Q1 group sales CHF 11.83B vs. CHF 11.50B
Subscribe for More Information
April 21, 2015
07:06 EDTRHHBYBina Tech, AstraZeneca announce collaborative agreement for GMS
Bina Technologies, a member of the Roche Group (RHHBY), and AstraZeneca (AZN) announced that they have entered into an agreement for AstraZeneca to become the first member to join the Bina Alliance Program and to further develop the Bina Genomic Management Solution. AstraZeneca will utilize the Bina GMS as an enterprise platform to support its development work across three main therapeutic areas: oncology, cardiovascular and metabolic disease, and respiratory, inflammation and autoimmunity. Bina’s proprietary technology enables translational and academic researchers to perform fast and scalable analyses to maximize the value of genomic data. Under the terms of the agreement, AstraZeneca will adopt Bina GMS globally to support enterprise genomic data analysis and management. Bina in turn will provide AstraZeneca with direct access to its scientific and engineering teams to further develop the Bina GMS for pharmaceutical applications.
05:33 EDTRHHBYInovio, Roche initiate clinical trial for DNA immunotherapy to treat HCB
Inovio Pharmaceuticals (INO) announced that it has initiated a Phase I trial to evaluate Inovio's DNA immunotherapy in patients who are chronically infected with hepatitis B. In 2013, Roche (RHHBY) and Inovio entered into a partnership to co-develop and commercialize Inovio's hepatitis B immunotherapy. This trial initiation triggers a $3M milestone payment from Roche to Inovio. This phase I, randomized, open-label, active-controlled, dose escalation study will evaluate the safety, tolerability, and immunogenicity of Inovio's hepatitis B immunotherapy, INO-1800, alone or in combination with INO-9112, Inovio's IL-12-based immune activator. This international study will enroll patients in the United States and Asia Pacific region with a primary endpoint of safety and tolerability of the therapy. The secondary endpoints will evaluate the cellular and humoral immune response to INO-1800 and investigate the therapy's effect on several viral and antiviral parameters. All trial subjects are also medicated with standard-of-care antiviral therapies.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use